B. Riley Securities Maintains Buy on Macrogenics, Raises Price Target to $11

Benzinga Newsdesk www.benzinga.com Positive 77.7%

Neg 0% Neu 0% Pos 77.7%

B. Riley Securities analyst Mayank Mamtani maintains Macrogenics (NASDAQ:MGNX) with a Buy and raises the price target from $9 to $11.